Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: A large-scale dose range-finding study

Journal of Infectious Diseases

Volumn 178, Issue 3, 1998, Pages 603-610

  Reitano, M ^b   Tyring, S ^b   Lang, W ^b   Thoming, C ^b   Worm, A M ^b   Borelli, S ^b   Chambers, L O ^a   Robinson, J M ^b   Corey, L ^b  

^a GLAXOSMITHKLINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; VALACICLOVIR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

EID: 0031688110     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515385     Document Type: Article

References (16)

1. Nahmias AJ, Lee FK, Beckman-Nahmias S. Seroepidemiological and sociological patterns of herpes virus infection in the world. Scand J Infect Dis Suppl 1990;69:19-36.
2. Johnson RE, Nahmias AJ, Magder LS, Lee FK, Brooks CA, Snowden CB. A Seroepidemiological survey of the prevalence of herpes simplex virus type-2 infection in the United States. N Engl J Med 1989;321:7-12.
3. Corey L. The current trend in genital herpes. Sex Transm Dis 1994;21(suppl 2):S38-S44.
4. Wald A, Zeh J, Barnum G, et al. Virologic characteristics of subclinical and symptomatic genital herpes infection. N Engl J Med 1995;333: 770-5.
5. Wagstaff AJ, Faulds D, Goa KL. Acyclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and .therapeutic efficacy. Drugs 1994;47:153-205.
6. Baker DA, Safrin S, Deeter RG, et al. Nine year effectiveness of continuous suppressive therapy with acyclovir (ACV) in patients with recurrent genital herpes (RGH). J Eur Assoc Dermoidal Venerol 1995;5(suppl 1):S169.
7. Tilson HH, Engle CR, Andrews EB. Safety of acyclovir: a summary of the first 10 years experience. J Med Virol 1993;1:67-73.
8. Mostow SR, Mayfield JL, Marr JJ, Drucker JL. Suppression of recurrent genital herpes by single daily dosages of acyclovir. Am J Med 1988; 85(suppl 2A):30-3.
9. Mindel A, Carney O, Freris M, Faherty A, Patou G, Williams P. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet 1988;1:926-8.
10. Weller S, Blum SR, Doucette M, et al. Pharmacokinetics of the acyclovir prodrug valaciclovir after single- and multiple-dose administration in normal volunteers. Clin Pharmacol Exp Ther 1993;54:595-605.
11. Soul-Lawton S, Seaber E, On N, et al. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 1995;39: 2759-64.
12. Patel R, Bodsworth NJ, Woolley P, et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once-daily therapy. Genitourin Med 1997;73:105-9.
13. Baker DA, Valaciclovir Study Group. Once daily valaciclovir for suppression of recurrent genital herpes in patients previously receiving 10 years of twice daily acyclovir suppressive therapy [abstract]. In: Program and abstracts of the 45th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (Las Vegas).
14. Quinn RP, Tadepalli S, Orban S, Gerald L. Immunoassay procedures, including RIA for detection of antiviral compounds: Zovirax and Retrovir as examples. In: Reid E, Wilson I, eds. Methodological surveys in biochemistry and analysis. Vol 20. Analysis for drugs and metabolites, including anti-infective agents. Cambridge, UK: Royal Society of Chemistry, 1990:185-94.
15. Freedman LS. Tables of the number of patients required in clinical trials using the log rank test. Stat Med 1982;1:121-9.
16. Mertz GJ, Jones CC, Mills J, et al. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. JAMA 1988;260:201-6.